Abstract
Background Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is commonly used to diagnose and stage lung cancer. In real-life practice, limitations are seen with cytology samples from EBUS-TBNA. Obtaining adequate samples can be challenging when faced with necrotic lesions with low cellular yield and the evolving landscape of targeted therapy, necessitating additional samples for comprehensive testing. Hence, transbronchial mediastinal cryobiopsy guided by endobronchial ultrasound (EBUS-TBMC) has emerged as a promising approach for obtaining larger tissue samples. In retrospective review, our aim is to present our early experience regarding the feasibility of performing EBUS-TBMC, employing a similar approach to EBUS-TBNA, followed by the outcomes of our procedures. We include a step-by-step explanation and some recommendations to conduct a successful EBUS-TBMC.
Method Single center retrospective analysis to evaluate the feasibility and utility of EBUS-TBMC cases over six months from July to December 2022.
Results 36 EBUS-TBMC procedures on 30 patients. Moderate sedation was used in 80% of cases. Majority (83.4%) of the patients had biopsy of a single lesion with a median of 3 cryobiopsies (Interquartile range 3-4). The median cryo-activation time was 6 seconds (Interquartile range 6-8). EBUS-TBMC demonstrated a positive yield of 86.1% with an overall diagnostic yield of 83.3%. Mild bleeding occurred in six biopsies (16.7%) which did not required further intervention. No other major complications were observed.
Conclusion EBUS-TBMC is a safe and effective alternative to EBUS-TBNA. Histology samples obtained through EBUS-TBMC have the potential to increase confidence in diagnosing and staging lung cancer, thereby alleviating concerns about tissue inadequacy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol received approval from the Medical Research and Ethics Committee, Ministry of Health Malaysia (NMRR ID-23-00577-6XP)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
